During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant-ineligible B-cell lymphoma.

As people age, their immune systems become less efficient, posing a challenge for cancer therapies that rely on harnessing immune cells.

Memorial Sloan Kettering Cancer Center investigators report that T cell interferon-γ (IFNγ) orchestrates a ...

The unusual molecular makeup of Borrelia burgdorferi, which causes Lyme disease, may hold clues for understanding and treating the tick-borne disease.

Results: The frequency of CD103 + CD69 + CD8 + Trm cells and CD14 + CD16 + monocytes was significantly higher in BA than in the control group. In BA, T cells showed elevated expression of CD103, CD69, ...

On identifying unique immune subsets enriched in HBV-related HCC, we further interrogated their phenotypes and functions using next-generation sequencing (NGS) and in vitro T-cell proliferation assays ...

Monoclonal B-cell lymphocytosis (MBL) is estimated to affect about 5–12% of people. It doesn’t cause symptoms and doesn’t require active treatment. However, a subtype called high-count MBL ...

"I wasn't happy that they were taking away our cell phones," he said. "But now I can see that it's really improved our school." After Polich spoke, Reynolds told him, "I want to share a secret ...

I’ve spent over a year with Buck Mason’s Pima cotton tee, and it’s my favorite T-shirt in my closet. It sits right below my hips, and the fit is roomy but still slim enough to wear under ...

AbCellera’s poster presentation is available for download here. About AbCellera’s T-Cell Engager Platform CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment.